MedPath Search

Found 540544 clinical trials

Sort by:

Robotic-assisted Bronchoscopy Under Moderate Sedation With Propofol

Not Applicable

Not yet recruiting

Conditions: Lung Lesions
Robotic Assisted Bronchoscopy
Propofol
Bronchoscopy
Bronchoscopy Biopsy

First Posted Date: 2025-06-05

Last Posted Date: 2025-06-05

Lead Sponsor: University of Zurich

Target Recruit Count: 30

Registration Number: NCT07006311

Transvaginal Diverticulum Wall Filling and Coverage Technique for Treating Female Circumferential Urethral Diverticulum

Phase 2

Not yet recruiting

Conditions: Circumferential Female Urethral Diverticulum

First Posted Date: 2025-06-05

Last Posted Date: 2025-06-05

Lead Sponsor: West China Hospital

Target Recruit Count: 30

Registration Number: NCT07006753

Locations: 🇨🇳
Sichuan University West China Hospital Department of Urology, Chengdu, Sichuan, China

Accuracy and Sustainability of SCALE-EYE Evaluation for Measuring Reliable Polyp Size

Not Applicable

Not yet recruiting

Conditions: Colorectal Polyps

First Posted Date: 2025-06-05

Last Posted Date: 2025-06-05

Lead Sponsor: Erasmus Medical Center

Target Recruit Count: 241

Registration Number: NCT07005453

The Application of Art Therapy to Patients Undergoing Hemodialysis Treatment

Not Applicable

Not yet recruiting

Conditions: Anxiety
Psychological Well-Being
Hemodialysis

First Posted Date: 2025-06-05

Last Posted Date: 2025-06-05

Lead Sponsor: EMİNE İNAL

Target Recruit Count: 70

Registration Number: NCT07005960

Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Gastric Adenocarcinoma
Stomach Neoplasms

Interventions: Drug: FLOT regimen
Drug: PD-1 Inhibitors
Drug: CAPEOX regimen
Drug: SOX regimen
Radiation: Para-aortic lymph node radiotherapy
Drug: Capecitabine

First Posted Date: 2025-06-05

Last Posted Date: 2025-06-05

Lead Sponsor: Jinbo Yue

Target Recruit Count: 54

Registration Number: NCT07007182

Effect of Niacinamide Supplementation in Glaucoma

Not Applicable

Active, not recruiting

Conditions: Primary Open-Angle Glaucoma (POAG)

First Posted Date: 2025-06-05

Last Posted Date: 2025-06-05

Lead Sponsor: University of Medicine and Pharmacy Craiova

Target Recruit Count: 100

Registration Number: NCT07007260

Locations: 🇷🇴
University of Medicine and Pharmacy of Craiova, Craiova, Dolj, Romania

Comparison of Traditional Dysphagia Therapy and Developed Protocol for Dysphagia Patients in Intensive Care Unit

Not Applicable

Not yet recruiting

Conditions: Dysphagia

First Posted Date: 2025-06-05

Last Posted Date: 2025-06-05

Lead Sponsor: Riphah International University

Target Recruit Count: 90

Registration Number: NCT07005427

Locations: 🇵🇰
Riphah International University Lahore Campus, Lahore, Punjab, Pakistan

Nicotinamide Levels in Serum, Aqueous Humor, and Tear Film in Glaucoma and Correlations With Mitochondrial Damage-Associated Molecular Patterns (mtDAMPs) and Senescence-Associated Secretory Phenotype (SASP)

Not Applicable

Not yet recruiting

Conditions: Glaucoma

First Posted Date: 2025-06-05

Last Posted Date: 2025-06-05

Lead Sponsor: Università degli Studi 'G. d'Annunzio' Chieti e Pescara

Target Recruit Count: 360

Registration Number: NCT07006194

Locations: 🇮🇹
Clinica Oftalmologica - Ospedale Clinicizzato SS Annunziata di Chieti, Chieti Scalo, Chieti, Italy
🇮🇹
U.O. Oculistica Universitaria, Pisa, Italy
🇮🇹
Clinica Oculistica AOU Sassari, Sassari, Italy

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

Phase 1

Not yet recruiting

Conditions: Small Cell Lung Carcinoma
Large Cell Neuroendocrine Carcinoma of the Lung
Neuroendocrine Prostate Cancer
Gastroenteropancreatic Neuroendocrine Carcinoma

Interventions: Drug: 225Ac-ETN029
Drug: 111In-ETN029

First Posted Date: 2025-06-05

Last Posted Date: 2025-06-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 116

Registration Number: NCT07006727

Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy

Phase 2

Not yet recruiting

Conditions: Breast Cancer Patients
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
HR+/HER2- Breast Cancer
Radiation Therapy

Interventions: Drug: Elacestrant
Radiation: PULSAR

First Posted Date: 2025-06-05

Last Posted Date: 2025-06-05

Lead Sponsor: Azienda Ospedaliero-Universitaria Careggi

Target Recruit Count: 21

Registration Number: NCT07005882

Locations: 🇮🇹
AOU Careggi Radiation Oncology Unit, Florence, Italy